Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605237 | 0.85 | ADORA1 (0.34) | FYNNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1605232 | 0.85 | SLC29A1 (0.34) | FYNNPC1RAB9ASMN1; SMN2KDM4E | |
| Bromide SCHEMBL6394519 | 0.84 | ADORA1 (0.33) | FYNNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1385640 | 0.82 | SMN1; SMN2 (0.42) | FYNNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL5023734 | 0.82 | FYN (0.32) | FYNKDM4EGAAELANE | |
| SCHEMBL1383700 | 0.82 | FYN (0.32) | FYNKDM4EGAAELANE | |
| SCHEMBL5450660 | 0.82 | SMN1; SMN2 (0.42) | FYNNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1386746 | 0.82 | SMN1; SMN2 (0.42) | FYNNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1384124 | 0.82 | SMN1; SMN2 (0.42) | FYNNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1605475 | 0.82 | FYN (0.32) | FYNKDM4EGAAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | AOC1 2668/4885AOC3 1762/4885FYN 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.